Recent data have demonstrated that aberrant promoter hypermethylation at CDKN2A locus independently affects p16INK4A and p14ARF, which are methylated in 27% and 57% of metastatic CM samples, respectively [37]. Here, CDKN2A is linked to cutaneous mastocytosis.